Validation and Cross-Linguistic Adaptation of the Frenchay Dysarthria Assessment (FDA-2) Speech Intelligibility Tests: Hebrew Version

Autor/inn/en	Icht, Michal; Bergerzon-Bitton, Orly; Ben-David, Boaz M.
Titel	Validation and Cross-Linguistic Adaptation of the Frenchay Dysarthria Assessment (FDA-2) Speech Intelligibility Tests: Hebrew Version
Quelle	In: International Journal of Language & Communication Disorders, 57 (2022) 5, S.1023-1049 (27 Seiten) PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	1368-2822
DOI	10.1111/1460-6984.12737
Schlagwörter	Speech Impairments; Articulation (Education); Psychomotor Skills; Intelligibility; Speech Evaluation; Correlation; Speech Tests; Hebrew; Sentences; Evaluation Criteria; Familiarity; Emotional Response; Older Adults; Scores; Comparative Analysis; Test Reliability; Speech Language Pathology; Culture Fair Tests; Contrastive Linguistics + Suchen Sie Ihr Suchwort? Speech impairment; Speech handicap; Speech handicaps; Language handicps; Language impairments; Sprachbehinderung; Articulation; Artikulation (Ling); Artikulation; Aussprache; Psychomotorische Aktivität; Korrelation; Sprechtest; Sentence analysis; Satzanalyse; Emotionales Verhalten; Älterer Erwachsener; Testreliabilität; Linguistics; Kontrastive Linguistik
Abstract	'Dysarthria' is a group of motor speech disorders resulting from a disturbance in neuromuscular control. Most individuals with dysarthria cope with communicative restrictions due to speech impairments and reduced intelligibility. Thus, language-sensitive measurements of intelligibility are important in dysarthria neurological assessment. The Frenchay Dysarthria Assessment, 2nd edition (FDA-2), is a validated tool for the identification of the nature and patterns of oro-motor movements associated with different types of dysarthria. The current study conducted a careful culture- and linguistic-sensitive adaption of the two intelligibility subtests of the FDA-2 to Hebrew (words and sentences) and performed a preliminary validation with relevant clinical populations. First, sets of Hebrew words and sentences were constructed, based on the criteria defined in FDA-2, as well as on several other factors that may affect performance: emotional valence, arousal and familiarity. Second, the new subtests were validated in healthy older adults (n = 20), and in two clinical groups (acquired dysarthria, n = 15; and developmental dysarthria, n = 19). Analysis indicated that the new subtests were found to be specific and sensitive, valid and reliable, as scores significantly differ between healthy older adults and adults with dysarthria, correlated with other subjective measures of intelligibility, and showed high test-retest reliability. The words and sentences intelligibility subtests can be used to evaluate speech disorders in various populations of Hebrew speakers, thus may be an important addition to the speech-language pathologist's toolbox, for clinical work as well as for research purposes. (As Provided).
Anmerkungen	Wiley. Available from: John Wiley & Sons, Inc. 111 River Street, Hoboken, NJ 07030. Tel: 800-835-6770; e-mail: cs-journals@wiley.com; Web site: https://www.wiley.com/en-us
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2024/1/01